By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Encore Therapeutics Inc. 

Carlsbad  California    U.S.A.
Phone: 619-787-4083 Fax:



Company News
Encore Therapeutics Inc. Announces Successful Proof of Concept Study on Meloxicam Depot Injection 10/18/2011 11:15:26 AM
Encore Therapeutics Inc. Announces Extended Release Depot Formulation of Ropivacaine Available for License 9/26/2011 10:40:38 AM
Progesterone and TBI: Encore Therapeutics Inc. Completes Novel Commercially Enabling Progesterone Formulation for TBI 5/10/2011 10:21:47 AM
Encore Therapeutics Inc. Announces Depot Meloxicam Formulation Enabling Local High Drug Dose Delivery 4/4/2011 8:09:37 AM
Encore Therapeutics Inc. Demonstrates Proof of Concept for a Long-acting Buprenorphine Depot for Pain and Drug Abuse Therapy (ETI-311) 12/8/2008 12:38:58 PM
PainReform Licenses a Novel Sustained Release Formulation of Ropivacaine from Encore Therapeutics Inc. 7/2/2008 9:52:11 AM
Novel Progesterone Formulation for Stroke and Traumatic Brain Injury Developed by Encore Therapeutics Inc. 6/24/2008 9:42:46 AM
Encore Therapeutics Inc. Reports Additional Proof of Concept Results on its Extended Release Ropivacaine Injectable Gel for Postoperative Pain Management 8/2/2007 1:12:26 PM
Encore Therapeutics Inc. Reports Efficacy Data On A Long-Acting Local Anesthetic Drug 1/30/2007 12:26:05 PM